Bruyère, O., Hiligsmann, M., Zegels, B., NEUPREZ, A., & Reginster, J.-Y. (September 2013). Risk of hip fracture in community-dwelling and institutionalized osteoporotic patients: A 3-year study. International Journal of Gerontology, 7 (3), 167-70. doi:10.1016/j.ijge.2012.11.015 |
Bruyère, O., Fossi, M., Zegels, B., LEONORI, L., Hiligsmann, M., Neuprez, A., & Reginster, J.-Y. (April 2013). Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria. Rheumatology International, 33 (4), 973-8. doi:10.1007/s00296-012-2460-y |
Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., Zegels, B., Maassen, P., Pire, G., & Reginster, J.-Y. (April 2013). Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX ) to assess the 10-year probability of fracture. Rheumatology International, 33 (4), 979-83. doi:10.1007/s00296-012-2461-x |
Zegels, B., LEONORI, L., Crozes, P., Uebelhart, D., Bruyère, O., & Reginster, J.-Y. (April 2013). Equivalence of a single dose (1200mg) compared to a 3-time a day dose (400mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis: Results of a randomized double blind placebo controlled study. Osteoporosis International, 24 (Suppl.1), 383. |
Bruyère, O., Zegels, B., Crozes, P., Uebelhart, D., & Reginster, J.-Y. (2013). Evaluation de l'amélioration cliniquement pertinente ressentie par les patients sous différents modes d'administration de sulfate de chondroïtine : résultats d'une étude randomisée, contrôlée et en double insu. Revue du Rhumatisme, 80 (S1), 123-A124. |
Zegels, B., Crozes, P., Uebelhart, D., Bruyère, O., & REGINSTER, J.-Y. (2013). Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis and Cartilage, 21 (1), 22-27. doi:10.1016/j.joca.2012.09.017 |
Bruyère, O., Ethgen, O., Neuprez, A., Zegels, B., Gillet, P., HUSKIN, J.-P., & Reginster, J.-Y. (2012). Health-related quality of life after total knee or hip replacement for osteoarthritis: a 7-year prospective study. Archives of Orthopaedic and Trauma Surgery. doi:10.1007/s00402-012-1583-7 |
Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., ZEGELS, B., Maassen, P., Pire, G., & Reginster, J.-Y. (June 2012). Perception, knowledge and use by general practitioners of Belgium of the FRAX tool. Annals of the Rheumatic Diseases, 71 (Suppl.3), 716. |
Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., Zegels, B., Maassen, P., Pire, G., & Reginster, J.-Y. (March 2012). Perception, knowledge and use by general practitioners of Belgium of the FRAX tool. Osteoporosis International, 23 (Suppl. 2), 363-364. |
Bruyère, O., Zegels, B., LEONORI, L., Rabenda, V., Janssen, A., Bourges, C., & Reginster, J.-Y. (March 2012). Effect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study. Osteoporosis International, 23 (Suppl. 2), 362-363. |
Bruyère, O., Zegels, B., Leonori, L., Rabenda, V., Janssen, A., Bourges, C., & Reginster, J.-Y. (2012). Effect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study. Complementary Therapies in Medicine, 20, 124-130. doi:10.1016/j.ctim.2011.12.007 |
Bruyère, O., Hiligsmann, M., Zegels, B., Neuprez, A., & Reginster, J.-Y. (March 2011). Risk of hip fracture in community-dwelling and institutionalized osteoporotic patients: a 3-year study. Osteoporosis International, 22 (Suppl.1), 332-333. |
Bruyère, O., Neuprez, A., Fossi, M., Zegels, B., LEONORI, L., Hiligsmann, M., & Reginster, J.-Y. (March 2011). Reimbursement of drugs against osteoporosis based on FRAX® instead of the current criteria would reduce by 30% the cost (in a societal perspective) of anti-osteoporosis treatment in Belgium. Osteoporosis International, 22 (Suppl.1), 333-334. |
Bruyère, O., Ethgen, O., Neuprez, A., Zegels, B., Gillet, P., Huskin, J.-P., & Reginster, J.-Y. (November 2010). Etude de la qualité de vie après la mise en place d’une prothèse de hanche ou de genou pour cause d’arthrose : une étude de cohorte avec un suivi de 7 ans. Revue du Rhumatisme, 77 (Suppl.3), 141. |
Bruyère, O., Hiligsmann, M., Zegels, B., Neuprez, A., & Reginster, J.-Y. (November 2010). Résider en institution : un facteur de risque indépendant de fractures de hanche ? Une étude prospective d’une durée de 3 ans. Revue du Rhumatisme, 77 (Suppl.3), 67-68. |
Bruyère, O., Neuprez, A., Fossi, M., Beaudart, C., Zegels, B., Leonori, L., Hiligsmann, M., & Reginster, J.-Y. (November 2010). Le remboursement des traitements contre l'ostéoporose basé sur l'utilisation de l'outil FRAX plutôt que sur les critères actuels permettrait de réduire de 30% le coût, dans une perspective sociétale, du traitement de l'ostéoporose en Belgique. Revue du Rhumatisme, 77 (Suppl.3), 66-67. |
Bruyère, O., Vanoverberghe, M., Neuprez, A., Ethgen, O., Zegels, B., Gillet, P., Huskin, J.-P., & Reginster, J.-Y. (June 2010). Health-related quality of life after total knee or hip replacement: a 7-year prospective study. Annals of the Rheumatic Diseases, 69 (Suppl.3), 469. |
Bruyère, O., Vanoverberghe, M., Neuprez, A., Ethgen, O., Zegels, B., Gillet, P., Huskin, J.-P., & Reginster, J.-Y. (May 2010). Health-related quality of life after total knee or hip replacement : a 7-year prospective study. Osteoporosis International, 21 (Suppl.1), 26. |
Zegels, B., Theiler, M., Crozes, P., Uebelhart, D., & Reginster, J.-Y. (May 2010). Single oral dose of (1200 mg) sachet of chondroitin 4&6 sulfate (CS) relieves pain and improves function. Results of a double-blind study, versus placebo and an active treatment in knee OA patients. Osteoporosis International, 21 (Suppl.1), 356. |
Reginster, J.-Y., Deroisy, R., NEUPREZ, A., Hiligsmann, M., Zegels, B., & Bruyère, O. (2009). Strontium ranelate: new data on fracture prevention and mechanisms of action. Current Osteoporosis Reports, 7 (3), 96-102. doi:10.1007/s11914-009-0016-1 |
Reginster, J.-Y., Hiligsmann, M., Rabenda, V., Zegels, B., Neuprez, A., & Bruyère, O. (2009). Ibandronate in the management of postmenopausal osteoporosis. Clinical Medicine. Therapeutics, 1, 1409-1421. |
ZEGELS, B., Theiler, R., Crozes, P., Uebelhart, D., & Reginster, J.-Y. (2009). Une prise orale unique (1200 mg) de sulfate de chondroïtine 4 & 6 (CS) réduit la douleur et améliore la fonction. Résultats d'une étude en double insu, contre placebo et un comparateur actif, chez des patients souffrants de gonarthrose (OA). Revue du Rhumatisme, 76, 1071. |
Bruyère, O., Pieck, C., Hiligsmann, M., Zegels, B., Delhez, M., Mottet, C., & Reginster, J.-Y. (June 2008). Place of residence as a risk factor for hip fracture? A case-control 3-year study. Annals of the Rheumatic Diseases, 67 (Suppl.II), 428. |
Bruyère, O., Pieck, C., Hiligsmann, M., Zegels, B., Delhez, M., Mottet, C., & Reginster, J.-Y. (April 2008). Place of residence as a risk factor for hip fracture? A case-control 3-year study. Osteoporosis International, 19 (Suppl.1), 200. |
Reginster, J.-Y., Collette, J., NEUPREZ, A., Zegels, B., Deroisy, R., & Bruyère, O. (10 February 2008). Role of Biochemical Markers of Bone Turnover as Prognostic Indicator of Successful Osteoporosis Therapy. BONE, 42, 832-836. doi:10.1016/j.bone.2008.01.021 |
Reginster, J.-Y., Heraud, F., Zegels, B., & Bruyère, O. (October 2007). Symptom and structure modifying properties of chondroitin sulfate in osteoarthritis. Mini Reviews in Medicinal Chemistry, 7 (10), 1051-1061. doi:10.2174/138955707782110088 |
Gadois, C., Zegels, B., Dohuu, J. P., Lespessailles, E., Neveu, J. P., Fardellone, P., Roux, C., Kolta, S., & Reginster, J.-Y. (March 2007). Effect of age on a fractal bone texture parameter assessed by high resolution digital X Ray: a multicenter pilot study. Osteoporosis International, 18 (Suppl.1), 102. |
Zegels, B., Theiler, R., Crozes, P., Uebelhart, D., & Reginster, J.-Y. (2007). Une prise orale unique (1200mg) de sulfate de chondroitine 4&6 (CS) réduit la douleur et améliore la fonction. Résultats d'une étude en double insu, contre placebo et un comparateur actif, chez des patients souffrant de gonarthrose (OA). In Revue du Rhumatisme. |
Manette, C., Collette, J., Sarlet, N., Tancredi, A., Zegels, B., & Reginster, J.-Y. (2006). Comprehensive therapy in osteoporosis using a single drug: From ADFR to strontium ranelate. Current Medicinal Chemistry, 13 (13), 1585-1590. doi:10.2174/092986706777442057 |
Deberg, M., Labasse, A., Christgau, S., Cloos, P., Bang Henriksen, D., Chapelle, J.-P., Zegels, B., Reginster, J.-Y., & Henrotin, Y. (March 2005). New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis and Cartilage, 13 (3), 258-265. doi:10.1016/j.joca.2004.12.002 |
Hanssens, L., Tancredi, A., DeCeulaer, F., Bruyère, O., Zegels, B., Halkin, V., Pire, G., Maassen, P., & Reginster, J.-Y. (May 2004). Evaluation of the relationship between IGF-1, IGF-BP3, BMD and age in men presenting at a multiple risk detection campaign. Osteoporosis International, 15 (Suppl.1), 48-49. |
Reginster, J.-Y., Sarkar, S., Zegels, B., Henrotin, Y., Bruyère, O., Agnusdei, D., & Collette, J. (February 2004). Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. BONE, 34 (2), 344-351. doi:10.1016/j.bone.2003.10.004 |
Deberg, M., Labasse, A., Christgau, S., Henriksen, D. B., Zegels, B., & Reginster, J.-Y. (November 2003). Cartilage degradation and oxidative damage in OA and RA patients. Osteoporosis International, 14 (Suppl. 7), 44-45. |
Ethgen, O., Tancredi, A., Lejeune, E., Kvasz, A., Zegels, B., & Reginster, J.-Y. (November 2003). Do utility values and willingness to pay suitably reflect health outcome in hip and knee osteoarthritis? A comparative analysis with the WOMAC index. Journal of Rheumatology, 30 (11), 2452-2459. |
Hanssens, L., Tancredi, A., De Ceulaer, F., Bruyère, O., Zegels, B., Halkin, V., Pire, G., Maassen, P., & Reginster, J.-Y. (November 2003). Evaluation of the relationship between IGF-I, IGF-BP3, BMD and age in men presenting at a multiple risk detection campaign. Osteoporosis International, 14 (Suppl. 7), 90-S91. |
Bruyère, O., Dardenne, C.-B., Lejeune, E., Zegels, B., Pahaut, A., Richy, F., Seidel, L., Ethgen, O., Henrotin, Y., & Reginster, J.-Y. (May 2003). Subchondral tibial bone mineral density predicts future joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis. BONE, 32 (5), 541-545. doi:10.1016/S8756-3282(03)00059-0 |
Bruyère, O., Lambert, V., Dardenne, C., Lejeune, E., Zegels, B., Pahaut, A., Richy, F., Seidel, L., Henrotin, Y., & Reginster, J.-Y. (November 2002). Subchondral tibial bone mineral density predicts joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis. Osteoporosis International, 13 (Suppl.3), 51-52. |
Ethgen, O., Tancredi, A., Lejeune, E., Zegels, B., Kvasz, A., & Reginster, J.-Y. (November 2002). A comparative analysis between the time trade-off and the willingness to pay approaches in hip and knee osteoarthritis. Osteoporosis International, 13 (Suppl. 3), 47. |
Bruyère, O., LAMBERT, V., Dardenne, C., Lejeune, E., Zegels, B., Richy, F., Seidel, L., Henrotin, Y., & Reginster, J.-Y. (September 2002). Subchondral tibial bone mineral density predicts joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis. Arthritis and Rheumatism, 16 (number 9 (suppl.)), 154. |
Ethgen, O., Tancredi, A., Lejeune, E., Zegels, B., Kvazs, A., & Reginster, J.-Y. (September 2002). Do willingness to pay and time trade-off approaches suitably reflect health outcomes in hip and knee osteoarthritis? Arthritis and Rheumatism, 46 (number 9 (suppl.)), 73. |
Sedrine, W. B., Chevallier, T., Zegels, B., Kvasz, A., Micheletti, M. C., Gelas, B., & Reginster, J.-Y. (June 2002). Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry. Gynecological Endocrinology, 16 (3), 245-250. doi:10.1080/gye.16.3.245.250 |
Reginster, J.-Y., Zegels, B., Lejeune, E., Micheletti, M. C., Kvsaz, A., Seidel, L., & Sarlet, N. (February 2002). Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion. Calcified Tissue International, 70 (2), 78-82. doi:10.1007/s00223-001-0034-1 |
Goemaere, S., Zmierczak, H., Van Pottelbergh, I., Toye, K., Daems, M., Zegels, B., Reginster, J.-Y., & Kaufman, J. M. (2002). Prediction of bone mineral density by estrogens precursors, estradiol, SHBG and BMI in elderly women at risk for osteoporotic fractures. Osteoporosis International, 13 (S1), 102. |
Ben Sedrine, W., Devogelaer, J. P., Kaufman, J. M., Goemaere, S., Depresseux, G., Zegels, B., Deroisy, R., & Reginster, J.-Y. (October 2001). Evaluation of the Simple Calculated Osteoporosis Risk Estimation (Score) in a Sample of White Women from Belgium. BONE, 29 (4), 374-80. doi:10.1016/S8756-3282(01)00583-X |
Reginster, J.-Y., Zegels, B., Lejeune, E., Micheletti, M. C., Taquet, A. N., & Albert, A. (February 2001). Influence of Daily Calcium and Vitamin D Supplementation on Parathyroid Hormone Secretion. Gynecological Endocrinology, 15 (1), 56-62. doi:10.1080/gye.15.1.56.62 |
Ben Sedrine, W., Devogelaer, J., Kaufman, J., Goemaere, S., Depresseux, G., Zegels, B., DEROISY, R., & Reginster, J.-Y. (2001). Evaluation of the simple calculated osteoporosis risk estimation in a sample of Caucasian women from Belgium. Clinical Rheumatology, 20, 420. |
Bruyère, O., Zegels, B., Dardenne, C.-B., Lejeune, E., Henrotin, Y., & Reginster, J.-Y. (2001). Measurement of the tibial subchondral bone mineral density: a potential tool for diagnosis and monitoring of knee osteoarthrits. Clinical Rheumatology, 5 (Suppl.1), 411. |
Bruyère, O., Zegels, B., Dardenne, C.-B., Lejeune, E., Henrotin, Y., & Reginster, J.-Y. (2001). Measurement of the tibial subchondral bone mineral density: a potential tool for diagnosis and monitoring of knee osteoarthrits. Osteoarthritis and Cartilage, 9 (Suppl.B), 61. |
Reginster, J.-Y., COLLETTE, J., Zegels, B., Henrotin, Y., Bruyère, O., & Durez, P. (2001). Relationship between 1-year change in bone turnover marker PINP and 3-year vertebral fracture risk reduction with raloxifene therapy in postmenopausal women with osteoporosis: result from the MORE trial. Clinical Rheumatology, 5 (Suppl.1), 425. |
Reginster, J.-Y., Sakar, S., COLLETTE, J., Zegels, B., Henrotin, Y., Bruyère, O., Wrong, M., Harper, K., & Agnusdei, D. (2001). Relationship between 1-year change in bone turnover marker PINP and 3-year vertebral fracture risk reduction with raloxifene therapy in postmenopausal women with osteoporosis: result from the MORE trial. BONE, 28 (Suppl.1), 239. |
Reginster, J.-Y., Zegels, B., DEROISY, R., Lejeune, E., & Taquet, A. (2001). The timing, dose and choice of calcium and vitamin D. BONE, S28, 253. |
Reginster, J.-Y., Zegels, B., Lejeune, E., Taquet, A., Micheletti, M., & Albert, A. (2001). Effect of daily regimen administration of calcium-vitamin D supplements on decrease of parathyroid hormone levels. BONE, S28, 244. |
Reginster, J.-Y., Zegels, B., Lejeune, E., Taquet, A., Micheletti, M., & Albert, A. (2001). Effect of a daily regimen administration of calcium-vitamin D supplements on decrease of parathyroid hormone levels. Clinical Rheumatology, 20, 424. |
Zegels, B., Eastell, R., Russell, R. G., Ethgen, D., Roumagnac, I., Collette, J., & Reginster, J.-Y. (January 2001). Effect of High Doses of Oral Risedronate (20 Mg/Day) on Serum Parathyroid Hormone Levels and Urinary Collagen Cross-Link Excretion in Postmenopausal Women with Spinal Osteoporosis. BONE, 28 (1), 108-12. doi:10.1016/S8756-3282(00)00410-5 |
Zmierczak, H., Goemaere, S., Daems, M., Toye, K., Zegels, B., Reginster, J.-Y., & Kaufman, J. (2001). Relationship between estrogen precursors, estradiol, body mass index and bone mineral dentiy in elderly women at risk of osteoporotic fractures. Clinical Rheumatology, 20, 422. |
Bruyère, O., COLLETTE, J., Zegels, B., Rovati, L. C., Seidel, L., Henrotin, Y., & Reginster, J.-Y. (2000). Baseline values and early (6-month) changes in total and bone specific alkaline phosphatase do not predict long-term (4-year) bone mineral density changes in postmenopausal osteoporotic women treated with fluoride. Arthritis and Rheumatism, 43 (S1), 199. |
Goemaere, S., Zegels, B., Toye, K., CREMERS, S., Demuynck, R., Daems, M., Dobbelaere, K., Ben Sedrine, W., Albert, A., Dewé, W., Kaufman, J., & Reginster, J.-Y. (1999). Limited clinical utility of a self-evaluating risk assessment scale for postmenopausal osteoporosis: lack of predictive value of lifestyle-related factors. Calcified Tissue International, 65 (5), 354-358. doi:10.1007/s002239900712 |
Reginster, J.-Y., Meurmans, L., Zegels, B., Rovati, L. C., Minne, H. W., Giacovelli, G., Taquet, A. N., Setnikar, I., Collette, J., & Gosset, C. (01 July 1998). The Effect of Sodium Monofluorophosphate Plus Calcium on Vertebral Fracture Rate in Postmenopausal Women with Moderate Osteoporosis. A Randomized, Controlled Trial. Annals of Internal Medicine, 129 (1), 1-8. doi:10.7326/0003-4819-129-1-199807010-00001 |
Reginster, J.-Y., Deroisy, R., Collette, J., Albert, A., & Zegels, B. (March 1997). Prediction of Bone Loss Rate in Healthy Postmenopausal Women. Calcified Tissue International, 60 (3), 261-4. doi:10.1007/s002239900226 |
Clemmesen, B., Ravn, P., Zegels, B., Taquet, A., Christiansen, C., & Reginster, J.-Y. (1997). A 2-year phase II study with 1-year of follow-up of risedronate (NE58095) in postmenopausal osteoporosis. Osteoporosis International, 7, 488-495. doi:10.1007/PL00004152 |
Goemaere, S., Zegels, B., Toye, K., Cremer, S., Demuynck, R., Vanheusden, E., Albert, A., Dewe, W., Kaufman, J., & Reginster, J.-Y. (1997). Diagnostic efficiency of a self-evaluating risk assessment for postmenopausal osteoporosis. Calcified Tissue International, 61, 502. |
Goemaere, S., Zegels, B., Toye, K., Cremer, S., Demuynck, R., Vanheusden, E., Albert, A., Dewe, W., Kaufman, J., & Reginster, J.-Y. (1997). Diagnosis efficiency of a self-evaluating risk assessment for postmenopausal osteoporosis. Journal of Bone and Mineral Research, 12 (S1), 495. |
Reginster, J.-Y., Deroisy, R., Zegels, B., Denis, D., Reginster-Haneuse, G., Wilkin, P., Taziaux, P., Albert, A., & Boelen, C. (1997). Prévention de l'ostéoporose à Liège. Evaluation d'un essai de partenariat entre médecins généralistes et spécialistes universitaires (1). Revue Médicale de Liège, 52 (1), 31-36. |
Reginster, J.-Y., Meurmans, L., Zegels, B., Rovati, L., Minne, H., Giacovelli, G., Taquet, A., Setnikar, I., & Collette, J. (1997). Sodium monofluorophosphate reduces vertebral fractures in moderate postmenopausal osteoporosis. Journal of Bone and Mineral Research, 12 (S1), 104. |
Reginster, J.-Y., Taquet, A. N., Fraikin, G., Gosset, C., & Zegels, B. (1997). Parathyroid hormone in the treatment of involutional osteoporosis : back to the future. Osteoporosis International, 7 (Suppl 3), 163-8. doi:10.1007/BF03194365 |
Deroisy, R., Pirenne, H., FREDERICK, I., Zegels, B., Taquet, A., Noel, V., Albert, A., & Reginster, J.-Y. (1996). Densité osseuse fémorale et carence vitaminique D dans une population de femmes âgées. Archives of Public Health, 53 (S1), 37. |
Meurmans, L., Zegels, B., Rovati, L., Taquet, A., & Reginster, J.-Y. (1996). Sodium monofluorophosphate reduces fracture incidence in women with postmenopausal osteoporosis : a randomized, placebo-controlled, double-blind study. Revue du Rhumatisme, 63, 672. |
Meurmans, L., Zegels, B., Rovati, L., Taquet, A., & Reginster, J.-Y. (1996). Réduction de l’incidence fracturaire vertébrale chez des femmes ostéoporotiques traitées par monofluorophosphate de sodium : une étude randomisée, placebo-controllée et double aveugle. Revue du Rhumatisme, 63, 788. |
Reginster, J.-Y., DEROISY, R., LECART, M.-P., Zegels, B., Denis, D., SARLET, N., Reginster-Haneuse, G., Albert, A., & Boelen, C. (1996). Prévention de l’ostéoporose à Liège. Histoire d’un PIGEPS : dix ans plus tard. Santé Publique: Revue Multidisciplinaire pour la Recherche et l'Action, 2, 139-150. |
Reginster, J.-Y., Zegels, B., Meurmans, L., Rovati, L., Taquet, A., Setnikar, I., & COLLETTE, J. (1996). Monofluorophosphate decreases vertebral fracture rate in postmenopausal osteoporosis: a randomised, placebo-controlled, double blind study. Osteoporosis International, 6 (S1), 239. |
Taquet, A., Clemmensen, B., Zegels, B., Ravin, P., Christiansen, C., Roumagnac, I., & Reginster, J.-Y. (1996). A three-year double-blind placebo-controlled study of risedronate in postmenopausal osteoporosis. Osteoporosis International, 6 (S1), 262. |
Zegels, B., Taquet, A., Eastell, R., Russell, R., Pack, S., & Reginster, J.-Y. (1996). Biochemical evidence of antiresorptive effect of risedronate in established osteoporosis. Osteoporosis International, 6 (S1), 249. |
Reginster, J.-Y., Deroisy, R., Lecart, M. P., Sarlet, N., Zegels, B., Jupsin, I., de Longueville, M., & Franchimont, P. (May 1995). A Double-Blind, Placebo-Controlled, Dose-Finding Trial of Intermittent Nasal Salmon Calcitonin for Prevention of Postmenopausal Lumbar Spine Bone Loss. American Journal of Medicine, 98 (5), 452-8. doi:10.1016/S0002-9343(99)80344-1 |
Reginster, J.-Y., Deroisy, R., Zegels, B., Jupsin, I., Albert, A., & Franchimont, P. (March 1995). Long-Term Performance in Vitro and in Vivo of Dual-Energy X-Ray Absorptiometry. Clinical Rheumatology, 14 (2), 180-6. doi:10.1007/BF02214940 |
Deroisy, R., Pirenne, H., Frederick, I., Zegels, B., Taquet, A., Noel, V., Zheng, Z., & Reginster, J.-Y. (1995). Femoral bone density and vitamin D deficiency in elderly women. Archives of Public Health, 52 (S1), 81. |
Deroisy, R., Pirenne, H., Frederick, I., Zegels, B., Taquet, A., Noel, V., Zheng, Z., & Reginster, J.-Y. (1995). Femoral bone density and vitamin D deficiency in elderly women. Journal of Bone and Mineral Research, 10 (S1), 463. |
Deroisy, R., Pirenne, H., Frederick, I., Zegels, B., Taquet, A., Noel, V., Zheng, Z., & Reginster, J.-Y. (1995). Densité osseuse fémorale et carence vitaminique D dans une population de femmes âgées. Revue du Rhumatisme, 10, 763. |
Reginster, J.-Y., Janssen, C., DEROISY, R., Zegels, B., Albert, A., & FRANCHIMONT, P. (1995). Bone mineral density of the spine and the hip measured with dual energy X-ray absorptiometry: normal range and fracture threshold for western European (Belgian) postmenopausal females. Clinical Rheumatology, 14 (1), 68-75. doi:10.1007/BF02208087 |
Zegels, B., Balena, R., Eastell, R., Russell, R., Pack, S., & Reginster, J.-Y. (1995). Effect of risedronate on collagen cross-links in postmenopausal osteoporosis. Journal of Bone and Mineral Research, 10 (s1), 455. |
Reginster, J.-Y., Denis, D., Bartsch, V., DEROISY, R., Zegels, B., & Franchimont, P. (1994). Acute biochemical variations induced by four different calcium salts in healthy male volunteers. Equilibre, 19, 5. |
Reginster, J.-Y., Denis, D., Deroisy, R., Lecart, M. P., De Longueville, M., Zegels, B., Sarlet, N., Noirfalisse, P., & Franchimont, P. (January 1994). Long-Term (3 Years) Prevention of Trabecular Postmenopausal Bone Loss with Low-Dose Intermittent Nasal Salmon Calcitonin. Journal of Bone and Mineral Research, 9 (1), 69-73. doi:10.1002/jbmr.5650090110 |
Reginster, J.-Y., Denis, D., Bartsch, V., Deroisy, R., Zegels, B., & Franchimont, P. (September 1993). Acute Biochemical Variations Induced by Four Different Calcium Salts in Healthy Male Volunteers. Osteoporosis International, 3, 271-5. doi:10.1007/BF01623832 |
Reginster, J.-Y., Gaspar, S., Deroisy, R., Zegels, B., & Franchimont, P. (September 1993). Prevention of Osteoporosis with Nasal Salmon Calcitonin: Effect of Anti-Salmon Calcitonin Antibody Formation. Osteoporosis International, 3, 261-4. doi:10.1007/BF01623830 |
Reginster, J.-Y., DEROISY, R., LECART, M.-P., Zegels, B., Sarlet, N., de Longueville, M., Albert, A., & Franchimont, P. (1993). Nasal salmon calcitonin for prevention of early postmenopausal bone loss: a dose-ranging placebo controlled study. Journal of Bone and Mineral Research, 8 (S1), 340. |
Reginster, J.-Y., Ethgen, D., Barbier, A., Geusens, P., Lecart, M., Chappard, D., de Vernejoul, M., Zegels, B., & Franchimont, P. (1993). Evidence that tiludronate is an interesting perspective for prevention and treatment of postmenopausal osteoporosis. Journal of Bone and Mineral Research, 8 (S1), 326. |
Reginster, J.-Y., Lecart, M.-P., Deroisy, R., Ethgen, D., Zegels, B., & Franchimont, P. (January 1993). Paget's Disease of Bone Treated with a Five Day Course of Oral Tiludronate. Annals of the Rheumatic Diseases, 52 (1), 54-7. doi:10.1136/ard.52.1.54 |
Reginster, J.-Y., Meurmans, L., Zegels, B., Darte, C., COLLETTE, J., DEROISY, R., & Franchimont, P. (1993). New radioimmunoassay for determination of bone specific iso-enzymes of serum alkaline phosphatases activity (Ostase°): validation and clinical perspective. Journal of Bone and Mineral Research, 8 (S1), 261. |
Reginster, J.-Y., Zegels, B., Meurmans, L., Bekkering, M., Rovati, L., Setnikar, I., & Franchimont, P. (1993). Efficacy and safety of monofluorophosphate and calcium in postmenopausal osteoporosis. Revista Espanola de Reumatologia: Organo Oficial de la Sociedad Espanola de Reumatologia, 20 (S1), 186. |
Reginster, J.-Y., DEROISY, R., Zegels, B., Lecart, M., Denis, D., & Franchimont, P. (1992). Intérêts et limites de l'absorptiométrie biphotonique dans le dépistage de l'ostéoporose postménopausique. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 511. |